Cartesian Therapeutics, Inc. financials

RNAC CIK 0001453687

Source: EDGAR filings · Built 2026-06-02T03:57:28Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -79.39M -32.77M -51.37M -32.83M -61.47M 34.07M
EBITDA -141.00M -42.70M -85.72M 15.24M -4.00M -56.22M
Working Capital 114.34M 193.65M 22.52M 123.06M 72.19M 69.80M
Net Debt -112.46M -198.63M -65.96M -94.78M -104.41M -128.13M
Operating Margin -35851.25% -114.69% -332.32% 13.12% -5.40% -342.36%
Net Margin -32575.50% -202.28% -844.91% 31.94% -30.19% -414.99%
Return on Equity (ROE) 103.22% 1138.25% 49.91% 37.71% -114.06% 382.52%
Return on Assets (ROA) -43.96% -17.80% -72.02% 21.33% -16.07% -41.63%
Current Ratio 8.65× 9.43× 1.33× 5.91× 2.00× 1.86×
Debt-to-Equity -0.10× -2.06× -0.02× 0.12× 0.43× -0.59×
Effective Tax Rate 6.59% -0.37% 7.96% -1.75% -164.24% 0.00%
Cash Conversion Ratio 0.57× 0.31× 0.23× -0.89× 2.35× -0.51×
Accruals Ratio -0.19× -0.12× -0.55× 0.40× 0.22× -0.63×
SBC % of Revenue 2630.25% 17.20% 86.62% 10.11% 9.07% 32.67%
CapEx Coverage -13.56× -2.60× -248.35× -26.34× -55.65× 42.80×
Free Cash Flow Per Share $-3.06 $-1.89 $-9.94 $-0.23 $-0.54 $0.34

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 11.30×
P/FCF 9.00×
FCF Yield 11.11%
EV / EBITDA 5.13×
P/S 468.85× 12.06× 0.14× 1.56× 4.74× 19.73×
P/B 1.84× 17.89×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 400.00K 38.27M 26.00M 110.78M 85.08M 16.60M
Revenues 2.80M 38.91M 26.00M
Research and Development Expense 58.03M 45.10M 71.26M 72.38M 68.74M 54.51M
Operating Expenses 146.20M 82.81M 112.42M 96.24M 89.67M 73.42M
Operating Income (Loss) -143.41M -43.90M -86.42M 14.54M -4.60M -56.82M
Income Tax Expense (Benefit) -9.19M 287.00K -19.00M -609.00K 15.97M 0
Net Income (Loss) Attributable to Parent -130.30M -77.42M -219.71M 35.38M -25.69M -68.88M
Earnings Per Share, Basic $-5.02 $-4.48 $-49.76 $0.24 $-0.22 $-0.68
Weighted Average Number of Shares Outstanding, Basic 25.97M 17.28M 5.17M 144.76M 114.33M 101.20M
Earnings Per Share, Diluted $-5.02 $-4.49 $-49.76 $0.10 $-0.22 $-0.68
Weighted Average Number of Shares Outstanding, Diluted 25.97M 17.36M 5.17M 145.87M 114.33M 101.20M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 125.14M 212.61M 76.91M 106.44M 114.06M 138.69M
Assets, Current 129.28M 216.63M 90.73M 148.14M 144.44M 151.34M
Assets 296.41M 435.02M 305.05M 165.89M 159.88M 165.44M
Liabilities, Current 14.94M 22.98M 68.21M 25.08M 72.25M 81.55M
Liabilities 422.65M 441.82M 444.68M 72.06M 137.36M 183.44M
Stockholders' Equity Attributable to Parent -126.24M -6.80M -440.18M 93.83M 22.52M -18.01M
Common Stock, Shares, Outstanding 26.01M 25.77M 5.40M 153.04M 123.62M 108.07M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -73.94M -23.67M -51.16M -31.63M -60.38M 34.88M
Payments to Acquire Property, Plant, and Equipment 5.45M 9.09M 206.00K 1.20M 1.08M 815.00K
Net Cash Provided by (Used in) Investing Activities -5.45M -8.74M 34.61M -15.00M -17.14M -741.00K
Net Cash Provided by (Used in) Financing Activities -8.05M 168.43M -13.14M 39.22M 52.90M 14.43M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RNAC CIK 0001453687), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

AQST

Aquestive Therapeutics, Inc.

GROV

Grove Collaborative Holdings, Inc.

PYXS

Pyxis Oncology, Inc.